-
Document de presse | 2025.03.31
MOPEVACLAS vaccine candidate for Lassa fever enters clinical trials
After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an original vaccine platform known as MOPEVAC, which will strengthen the Institut Pasteur's pandemic preparedness initiatives. A Phase Ia clinical trial led by a research team at the Institut Pasteur is set to begin for the platform's first vaccine candidate, which targets Lassa fever...
-
Article | 2018.07.12
MOOC HIV SCIENCE
HIV infection remains an outstanding global health issue despite the dramatic progress made over the past 35 years in developing and giving access to prevention and treatment tools. There are still 2 million new infections and 1 million deaths every year. Half of the 37 million people living with HIV do not have access to life-saving antiretroviral treatments. Although these molecules are...
-
News | 2014.11.19
Chikungunya fever: Themis Bioscience’s vaccine candidate successful in phase 1
The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate was developed under a R&D collaboration between Themis Bioscience GmbH and the...
-
News | 2018.01.11
Frédéric Tangy, expert from the Institut Pasteur, talks about vaccines of today and tomorrow
In 2017, vaccinology expert Frédéric Tangy was recognized by the Institut Pasteur for his work on the Measles Platform and was elected as a member of the US National Academy of Inventors. As the Institut Pasteur enters its 130th year – it will be celebrating its 130th anniversary on November 14, 2018 – it seemed like a good opportunity to ask the scientist to tell us a little more about his...
-
Article | 2020.06.12
Development of an animal model and accelerated development of a DNA vaccine candidate
Aims:To develop a mouse model of SARS-CoV-2 infection.This will not only enable us to evaluate the efficacy of the vaccine; it will also facilitate in vivo research on SARS-CoV-2. To evaluate the immunogenicity (ability to induce a specific immune reaction) and efficacy (protection capability) of DNA-based vaccine candidates.DNA vaccination is a technique for protecting against...
-
Document de presse | 2020.03.19
CEPI collaborates with the Institut Pasteur in a consortium to develop Covid-19 vaccine
Consortium to be led by the Institut Pasteur and will include Themis and the University of Pittsburgh.CEPI to provide initial US$4.9 million for consortium to develop a Covid-19 vaccine candidate based on measles-vector technology.Partnership becomes eighth Covid-19 vaccine development project that CEPI has signed since Jan 23, 2020 OSLO, NORWAY, March 19, 2020 – CEPI, the Coalition for...
-
Document de presse | 2009.08.24
Whooping cough: increase in vaccine coverage, decrease in bacterial virulence
The whooping cough monitoring carried out in France has enabled Institut Pasteur and CNRS researchers to analyze Bordetella pertussis, the bacterium responsible for whooping cough. For the first time, among the strains in circulation, they have identified bacteria not expressing some of the virulence factors targeted by the vaccine, such as the bacterial toxin. These observations confirm the...
-
News | 2015.01.13
Identification of an Achilles heel in the dengue virus gives new hope for vaccine development
Scientists have identified a vulnerable site on the surface of the dengue virus which is targeted by the only broadly neutralizing antibodies identified to date. This discovery offers a new target for the development of a vaccine to combat all four types of dengue virus currently in circulation.
-
News | 2024.12.20
Signing of a Memorandum of Understanding between the Institut Pasteur and the International Vaccine Institute (IVI)
The Institut Pasteur and the International Vaccine Institute (IVI) are strengthening their commitment to global health by signing a Memorandum of Understanding (MoU), marking a new milestone in their collaboration. The official ceremony took place on December 19, 2024, on the Institut Pasteur campus in Paris, in the presence of Yasmine Belkaid, Director General of the Institut Pasteur, and Dr....
-
News | 2023.04.28
Lassa fever: promising results for a vaccine candidate in a Phase I clinical trial
The Lassa arenavirus causes hemorrhagic fever and is a major problem in many West African countries, claiming 5,000 to 6,000 lives every year. There is therefore an urgent need to develop treatments and prepare for potential outbreaks. An international study involving Institut Pasteur researchers has reported the results of Phase I clinical trial for a Lassa fever vaccine. Vaccine candidates...